# US 2016/0353994 A9 · Method for the analysis of progression of heterotopic ossification by Raman spectroscopy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0353994 A9
- Document ID: US20160353994A9
- Status: Published application
- Kind: A9
- Application number: 14/146,334
- Filed: 2014-01-02
- Published: 2016-12-08
- Earliest claimed: 2013-01-04
- Inventors: Nicole Crane; Eric A. Elster; Jonathan Forsberg; Douglas Tadaki
- Web page: https://patentgrep.com/patent/US20160353994A9

## CPC

- A61B 5/0075: {by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence)}
- A61B 5/0084: {for introduction into the body, e.g. by catheters (A61B5/1459 takes precedence)}
- A61B 5/4504: {Bones (A61B5/4547 takes precedence)}
- A61B 5/4519: {Muscles (measuring muscular strength A61B5/224; using electromyography [EMG] A61B5/389)}
- A61B 5/4842: {Monitoring progression or stage of a disease}
- A61B 6/505: {for diagnosis of bone}
- A61B 6/5217: {extracting a diagnostic or physiological parameter from medical diagnostic data}
- A61B 10/02: Instruments for taking cell samples or for biopsy {(A61B10/0038 and A61B10/0045 take precedence; needle locating or guiding means A61B17/3403; samplers for enzymology or microbiology C12M1/26; sampling or preparing biological specimens G01N33/48)}
- G01N 21/65: Raman scattering
- G01N 33/4833: {of solid biological material, e.g. tissue samples, cell cultures (tissue in vivo A61B5/00; cell suspensions G01N33/48735)}
- A61B 2505/05: Surgical care
- G01J 3/4412: {Scattering spectrometry (particle sizing by light scattering G01N15/0205; optical velocimetry of particles G01P5/20, G01P5/26)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G01J: MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY (light sources F21, H01J, H01K, H05B; investigating properties of materials by optical means G01N)

## Abstract

A method for detecting and monitoring the progression of heterotopic ossification by Raman spectral analysis. Analysis of heterotopic ossification progress can be conducted using invasive or invasive means using specific Raman spectroscopy. Analysis is by determination of a number of Raman spectral parameters including the area under one or more of the vibrational bands, band area ratios, band height, ratios of band heights and shift in band center.

## Claims

### Claim 1

A method for analyzing heterotopic ossification comprising determining the presence, maturity or composition of heterotopic ossification by determining one or more Raman spectral measurements of one or more Raman spectral bands, wherein said Raman spectral measurements are selected from the group consisting of band area, band center, band area ratios, band height, ratio of band height, increase or decrease from band center, and band area ratio.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more Raman spectral bands are selected from the group consisting of 1445 cm−1, 945 cm−1; 960 cm−1; and 1070 cm−1; and wherein two or more of said band areas are used in computing band area ratios, wherein said band area ratios are selected from the group consisting of 945 cm−1/960 cm−1, 1070 cm−1/960 cm−1, 960/1445, and 1070/1445 cm−1.

### Claim 3 (depends on 1)

The method of claim 1, wherein said determining of band area or computing of said band area ratios are made over a time period to determine the progression of heterotopic ossification.

### Claim 4 (depends on 1)

The method of claim 1, wherein said determining of composition and maturity of heterotopic ossification is the detection of mineralization of soft tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein said composition is mineral crystallinity, wherein said mineral crystallinity is determined by measuring the full width at half maximum of the 960 cm−1 Raman spectral band.

### Claim 6 (depends on 1)

The method of claim 1, wherein said method also includes the step of determining traumatized region of tissue prior to determining said area under multiple Raman vibrational bands associated with heterotopic ossification.

### Claim 7 (depends on 1)

The method of claim 1, wherein said Raman spectral measurements are collected by invasive or noninvasive means.

### Claim 8 (depends on 1)

The method of claim 1, wherein said Raman spectral bands comprise one or more bands selected from the group consisting of 1660, 1445, 1640, 1240, 1270, and 1340, and wherein said computing of band area ratios comprises one or more band area ratios selected from the group consisting of 1660/1445 cm−1, 1680/1445 cm−1, 1640/1445 cm−1, 1640/1660 cm−1, 1240/1270 cm−1, and 1340/1270 cm−1.

### Claim 9 (depends on 2)

The method of claim 2, wherein said Raman spectral bands also comprises one or more of the vibrational bands selected from the group consisting of 591 cm−1, 1003 cm−1, 921 cm−1, 876 cm−1 855 cm−1 and 1045 cm−1.

### Claim 10 (depends on 2)

The method of claim 2, wherein mature heterotopic ossification is detected as a 50% decrease cm−1 of the mineral-to-matrix ratio by measuring the band area ratio 960/1445 cm−1.

### Claim 11 (depends on 2)

The method of claim 2, wherein said early or mature HO is determined by an increase in said Raman band area ratio 1070/960 cm−1 over said time period over normal bone.

### Claim 12 (depends on 2)

The method of claim 2, wherein HO is determined as a greater than 3 cm−1 increase of the 1445 cm−1 band center.

### Claim 13 (depends on 2)

The method of claim 2, wherein mature HO is detected as a 40% or greater decrease in 945/960 cm−1 band area ratio from immature HO and wherein early HO is detected as at least a 40% increase in the 945/960 cm−1 band area ratio over normal bone.

### Claim 14 (depends on 2)

The method of claim 2, wherein mature HO is determined as a greater than 3 cm−1 increase from the 1070 cm−1 band center for early HO.

### Claim 15 (depends on 2)

The method of claim 2, wherein mature HO is determined as a greater than 60% increase in the 1070/1445 cm−1 band area ratio from normal bone.

### Claim 16 (depends on 2)

The method of claim 2, wherein mature HO is determined as a greater than 2 cm−1 decrease in the 945 cm−1 band center normal bone.

### Claim 17 (depends on 2)

The method of claim 2, wherein mature HO is determined by a greater than 5% increase compared to bone in mineral crystallinity, wherein mineral crystallinity is determined by 960 cm−1 band width at half maximum.

### Claim 18 (depends on 2)

The method of claim 2, wherein mature HO is determined by a 50% or greater increase in standard deviation compared to bone at the band area ration 960/1445 cm−1.

### Claim 19 (depends on 6)

The method of claim 6, wherein said determination of traumatized region of tissue is conducted by x-ray analysis or Raman spectral analysis.

### Claim 20 (depends on 7)

The method of claim 7, wherein said data from invasive means includes the additional step of collection of one or more biopsy samples.

### Claim 21 (depends on 7)

The method of claim 7, wherein said noninvasive means comprises a fiber optic probe-coupled system.

### Claim 22 (depends on 8)

The method of claim 8, wherein mature HO is determined as a least a 60% decrease of the 1340/1270 cm−1 band height ratio and wherein early HO is determined as at least a 20% decrease of the 1340/1270 cm−1 band height compared to muscle.

### Claim 23 (depends on 8)

The method of claim 8, wherein mature HO is determined as a 50% or greater decrease in the 1340/1270 cm−1 band height ratio or the 1340/1270 cm−1 band area ratio compared to early HO.

### Claim 24 (depends on 8)

The method of claim 8, wherein mature HO is determined by a 25% or greater decrease in the 1660/1445 cm−1 band area ratio compared to muscle or early HO.

### Claim 25 (depends on 8)

The method of claim 8, wherein HO is determined by a two times or greater increase of the 1640/1660 cm−1 band area ratio over muscle.

### Claim 26 (depends on 8)

The method of claim 8, wherein HO is determined by a 2 cm−1 increase from the 1660 cm−1 band center of muscle.

### Claim 27 (depends on 9)

The method of claim 9, wherein mature HO is determined as a greater than 10 cm−1 increase from said 1045 cm−1 band center.
